
🗽 NY Company • 📦 Domestic FedEx / UPS • 🌐 Global Shipping • 🔬 99% Purity Certified & COA Available
•Structural Evaluation: CJC-1295 no dac vial
Comprehensive molecular profile and audited data regarding growth hormone secretagogue pathways.
1. Technical Overview & Signaling
- Structural Backbone: CJC-1295 without DAC operates as a modified 30-amino acid peptide analogue designed to engage with GHRH receptor axes. Also documented as Modified GRF(1-29), it features amino acid substitutions engineered to optimize stability.
- Stability Differences: Unlike its DAC-conjugated variant, this compound excludes the maleimido_propionyl-lysine drug affinity moiety, resulting in a short, pulsatile window of interaction within laboratory models.
- Research Focus: In vitro and preclinical evaluations analyze its distinct capacity to model baseline endogenous somatotroph secretions without inducing constant, uninterrupted activation cascades.
2. Assayed Chemical Properties
3. Comparative Research Literature
- GRF Substitutions: Academic nomenclature references tetrasubstituted chains (D-Ala2, Gln8, Ala15, Leu27) tailored to resist rapid enzyme breakdown when evaluated inside in vitro assays.
- Pulsatile Dynamics: Research records choose this specific form over the sustained DAC variation to map real-time cellular response spikes, closely matching standard biological growth patterns under study.
4. Audited Regulatory Status
99%+ Guaranteed
Tested Batches
Grade Distribution
Use Specifications
⚠️ FDA DISCLAIMER: These products are intended strictly for laboratory research use only. They are not intended for human consumption, diagnostic, or therapeutic purposes. The statements on this website have not been evaluated by the Food and Drug Administration.





